GSA Capital Partners LLP Decreases Position in Humacyte, Inc. (NASDAQ:HUMA)

GSA Capital Partners LLP lessened its holdings in shares of Humacyte, Inc. (NASDAQ:HUMA) by 54.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 199,049 shares of the company’s stock after selling 238,032 shares during the period. GSA Capital Partners LLP owned approximately 0.17% of Humacyte worth $619,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in HUMA. Whittier Trust Co. of Nevada Inc. purchased a new stake in shares of Humacyte during the 4th quarter valued at $28,000. SG Americas Securities LLC raised its stake in Humacyte by 52.8% in the 4th quarter. SG Americas Securities LLC now owns 16,340 shares of the company’s stock worth $46,000 after acquiring an additional 5,645 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Humacyte by 350.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,986 shares of the company’s stock worth $34,000 after acquiring an additional 9,325 shares during the last quarter. United Asset Strategies Inc. raised its stake in Humacyte by 53.9% in the 4th quarter. United Asset Strategies Inc. now owns 221,308 shares of the company’s stock worth $629,000 after acquiring an additional 77,500 shares during the last quarter. Finally, Powell Investment Advisors LLC raised its stake in Humacyte by 75.0% in the 4th quarter. Powell Investment Advisors LLC now owns 21,000 shares of the company’s stock worth $60,000 after acquiring an additional 9,000 shares during the last quarter. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Price Performance

Shares of HUMA opened at $6.99 on Friday. The business’s 50-day moving average is $6.23 and its two-hundred day moving average is $4.37. The company has a market capitalization of $832.37 million, a P/E ratio of -6.99 and a beta of 1.51. The company has a debt-to-equity ratio of 0.61, a quick ratio of 8.37 and a current ratio of 8.37. Humacyte, Inc. has a fifty-two week low of $1.96 and a fifty-two week high of $9.97.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Friday, May 10th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Research analysts predict that Humacyte, Inc. will post -0.95 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Brady W. Dougan sold 271,518 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $7.30, for a total transaction of $1,982,081.40. Following the sale, the director now directly owns 4,559,140 shares in the company, valued at approximately $33,281,722. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Laura E. Niklason sold 809,786 shares of the firm’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $7.91, for a total transaction of $6,405,407.26. Following the sale, the chief executive officer now directly owns 5,381,354 shares in the company, valued at approximately $42,566,510.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Brady W. Dougan sold 271,518 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $7.30, for a total value of $1,982,081.40. Following the sale, the director now owns 4,559,140 shares in the company, valued at $33,281,722. The disclosure for this sale can be found here. In the last three months, insiders have purchased 54,412 shares of company stock valued at $369,107 and have sold 1,628,820 shares valued at $12,464,121. 23.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 target price on shares of Humacyte in a research note on Tuesday, July 2nd. Piper Sandler restated a “neutral” rating and issued a $4.00 target price on shares of Humacyte in a research note on Tuesday, March 26th. Finally, Benchmark restated a “buy” rating and issued a $15.00 target price on shares of Humacyte in a research note on Tuesday, July 2nd.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.